Resource Logo

[No HCV seroconversion in hemophilia following substitution with virus-inactivated coagulation factor VIII and IX concentrates]


Schweiz Med Wochenschr. 1991 Nov 2;121(44):1621-3. Unique Identifier :

Since 1986 the factor VIII and IX concentrates of the Central Laboratory, Swiss Red Cross Blood Transfusion Service have been virus inactivated with tri-(n-butyl) phosphate and Tween 80. Clinical studies had shown that both preparations were well tolerated and hemostatically effective; no HIV infection was transmitted. However, safety from transmission of non-A/non-B hepatitis could not be shown since the study included no previously untreated patients. In the meantime, a laboratory test has become available which allows retrospective testing for anti-hepatitis C antibodies in frozen sera of the study patients. 5 of the 26 patients, observed during a 2-year follow-up study, had no HCV antibodies before entering the long-term trial. During this trial, each of these 5 patients substituted an average quantity of 40,200 coagulation factor units (7500-69,000) from 45 production lots. None of these 5 patients developed anti-HCV antibodies, nor did any of them show clinical signs of infection with hepatitis. This suggests that virus inactivation using solvent/detergent treatment reduces the risk of transmission of HCV.

Blood Coagulation Disorders/IMMUNOLOGY/*THERAPY *Blood Transfusion English Abstract Hepatitis Antibodies/ISOLATION & PURIF Hepatitis C/PREVENTION & CONTROL/*TRANSMISSION Hepatitis C Viruses/*DRUG EFFECTS/IMMUNOLOGY Human Phosphoric Acid Esters/PHARMACOLOGY Polysorbates/PHARMACOLOGY JOURNAL ARTICLE


Information in this article was accurate in February 28, 1992. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.